Bulk Pharmaceutical API Sources for cefixime

Bulk Pharmaceutical API Sources for cefixime

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-003-845-687
Hangzhou APIChem Technology		AC-4350
Oakwood Products		036523

CEFIXIME BULK ACTIVE PHARMACEUTICAL INGREDIENT (API) SOURCES

Last updated: February 19, 2026

This report identifies key global suppliers of bulk Cefixime active pharmaceutical ingredient (API), detailing their manufacturing capabilities, regulatory compliance, and primary markets. Data is derived from patent filings, regulatory agency databases, and industry trade publications.

What is Cefixime API and Its Therapeutic Use?

Cefixime is a third-generation cephalosporin antibiotic used to treat a variety of bacterial infections. It functions by inhibiting bacterial cell wall synthesis, leading to bacterial lysis and death. Its spectrum of activity includes many Gram-positive and Gram-negative organisms, making it effective against infections such as bronchitis, urinary tract infections, otitis media, pharyngitis, and gonorrhea. The global demand for Cefixime API is driven by its established efficacy and broad application in primary care and specialized infectious disease treatment.

Who are the Primary Manufacturers of Cefixime API?

Key manufacturers of Cefixime API are concentrated in Asia, with China and India dominating production. Several companies possess substantial manufacturing capacity and adhere to international quality standards.

• China:

  • Nanjing Pharma Technologies Co., Ltd.: Specializes in antibiotic APIs, including Cefixime. The company operates multiple production facilities, with a significant portion dedicated to cephalosporin synthesis. Its primary markets include Southeast Asia, South America, and Eastern Europe.
  • Zhejiang NHU Company Ltd.: A diversified chemical and pharmaceutical manufacturer with a significant API division. NHU has invested in advanced fermentation and synthesis technologies for antibiotic production. Their Cefixime API is supplied globally, with a strong presence in regulated markets.
  • Shandong Xinhua Pharmaceutical Co., Ltd.: A long-standing pharmaceutical manufacturer with extensive experience in antibiotic production. Xinhua produces Cefixime API in bulk quantities, meeting pharmacopoeial standards from USP, EP, and JP. Their export focus includes North America and Europe.
  • Lianbang Pharmaceutical Group Co., Ltd.: Focuses on the research, development, and production of cephalosporin antibiotics. Lianbang has a dedicated Cefixime production line with a capacity exceeding 500 metric tons annually. They serve both domestic Chinese and international markets.

• India:

  • Divi's Laboratories Limited: A major global supplier of APIs and intermediates. Divi's has a large-scale manufacturing facility for cephalosporin APIs, including Cefixime, equipped with advanced environmental controls and quality assurance systems. They are a significant exporter to the U.S. and European markets.
  • Aurobindo Pharma Limited: A vertically integrated pharmaceutical company with a strong API manufacturing base. Aurobindo produces Cefixime API under stringent GMP conditions, supplying to over 100 countries. Their facilities are approved by major regulatory bodies.
  • Dr. Reddy's Laboratories: While known for finished formulations, Dr. Reddy's also produces select APIs. Their Cefixime API production is characterized by adherence to high-quality standards and a focus on innovation in synthesis processes. They supply to both regulated and emerging markets.
  • Strides Pharma Science Limited: Produces a range of APIs, with a focus on antibiotics. Strides has a dedicated Cefixime API manufacturing unit, emphasizing efficiency and cost-effectiveness. Their global reach extends to Asia, Africa, and Latin America.

What are the Regulatory and Quality Standards for Cefixime API Manufacturing?

Manufacturing of Cefixime API must comply with stringent international regulatory requirements to ensure product safety, efficacy, and quality. These standards are enforced by national drug regulatory authorities and international bodies.

• Good Manufacturing Practices (GMP): Compliance with current GMP (cGMP) is mandatory. This includes guidelines from the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO). Key aspects of GMP include process validation, quality control, documentation, and facility hygiene.
• Pharmacopoeial Standards: Cefixime API must meet the specifications outlined in major pharmacopoeias, including:
  • United States Pharmacopeia (USP)
  • European Pharmacopoeia (EP)
  • Japanese Pharmacopoeia (JP)
  • Indian Pharmacopoeia (IP) These standards define acceptable limits for purity, impurities, assay, and physical characteristics.
• Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): Manufacturers typically file DMFs (in the U.S.) or ASMFs (in Europe) with regulatory authorities. These confidential documents detail the manufacturing process, quality control measures, and stability data for the API, allowing finished drug product manufacturers to reference them in their marketing authorization applications.
• Inspections and Audits: API manufacturing sites are subject to routine inspections by regulatory agencies (e.g., FDA, EMA) and audits by customers. Successful inspection outcomes are critical for market access, particularly in regulated markets like the U.S. and EU.

What are the Key Patent Landscape Considerations for Cefixime API?

While the primary patents covering the Cefixime molecule have expired, ongoing patent activity focuses on novel synthesis routes, crystalline forms, and purification processes. These innovations can provide a competitive edge and intellectual property protection.

• Synthesis Process Patents: Many patents filed in recent years claim specific chemical reactions, catalysts, or solvent systems for producing Cefixime with improved yield, purity, or reduced environmental impact. For example, patents may describe methods for the stereoselective synthesis of the Cefixime side chain or novel approaches to ring closure.
  • Example: A patent might claim a novel catalytic method for the formation of the Cefixime enol ether moiety, improving the efficiency of this critical step.
• Polymorphism and Crystalline Forms: Patents may also cover specific crystalline forms (polymorphs) of Cefixime, which can affect its solubility, stability, and bioavailability. Controlling polymorphism is crucial for consistent drug product performance.
  • Example: A patent could claim a specific anhydrous or hydrated crystalline form of Cefixime with superior long-term storage stability.
• Impurity Profiling and Control: Patents may also address methods for identifying, quantifying, and controlling specific impurities that arise during Cefixime synthesis. This is particularly relevant for meeting stringent regulatory limits on genotoxic or process-related impurities.
• Patent Expirations: The original composition of matter patents for Cefixime have long expired, allowing for generic manufacturing. However, the expiration of process or polymorph patents can open new avenues for generic manufacturers to adopt more efficient or proprietary production methods.
• Geographic Filing Strategies: Companies active in Cefixime API patenting often file in major pharmaceutical markets, including the United States, Europe (via European Patent Office), China, India, and Japan, to secure broad protection.

What are the Market Dynamics and Pricing Trends for Cefixime API?

The Cefixime API market is characterized by competitive pricing, driven by a large number of manufacturers, particularly in China and India. Pricing is influenced by raw material costs, production scale, regulatory compliance costs, and market demand.

• Price Volatility: Raw material prices, especially those for key intermediates in cephalosporin synthesis, can impact Cefixime API costs. Fluctuations in the prices of 7-aminocephalosporanic acid (7-ACA) or its precursors can lead to price shifts.
• Scale of Production: Larger manufacturers with economies of scale can generally offer more competitive pricing. Companies investing in high-capacity, automated production lines often achieve lower per-unit costs.
• Regulatory Costs: Maintaining GMP compliance, conducting stability studies, and preparing DMFs/ASMFs incur significant costs. Manufacturers with strong regulatory track records and approved facilities in multiple regions may command slightly higher prices due to reduced perceived risk for buyers.
• Geographic Demand: Demand from emerging markets in Asia, Africa, and Latin America is a significant driver of API volume. While prices in these regions may be lower, they contribute to overall production utilization.
• Contract Manufacturing: Some companies may engage in contract manufacturing for Cefixime API, further influencing pricing dynamics. This can lead to highly competitive bids for large volume contracts.
• Typical Price Range: While subject to negotiation and volume, bulk Cefixime API pricing can range from approximately $25 to $50 per kilogram, depending on the supplier's quality certifications, origin, and purity specifications.

What are the Key Supply Chain Considerations?

A robust Cefixime API supply chain requires careful management of raw material sourcing, manufacturing, quality assurance, and logistics.

• Raw Material Sourcing: The availability and cost of key starting materials, such as 7-ACA or related cephalosporin nuclei, are critical. Diversifying sources of these intermediates can mitigate supply risks.
• Manufacturing Capacity: Ensuring access to sufficient manufacturing capacity is paramount, especially during periods of high demand. Manufacturers with multiple production sites offer greater supply security.
• Quality Control and Assurance: Rigorous quality control at every stage of production, from raw materials to finished API, is essential. This includes in-process testing and final product release testing against pharmacopoeial standards.
• Logistics and Distribution: Efficient transportation and storage are necessary to maintain API integrity. Temperature and humidity controls during shipping are often required. Global distribution networks are crucial for reaching diverse customer bases.
• Regulatory Approvals: Securing and maintaining regulatory approvals in target markets (e.g., FDA, EMA) is a prerequisite for most buyers in regulated territories. Manufacturers with established DMFs and successful inspection histories have an advantage.
• Geopolitical Risks: Political instability, trade disputes, or environmental regulations in key manufacturing regions can impact supply chain reliability. Diversification of supplier locations can help mitigate these risks.

What are the Future Outlook and Emerging Trends for Cefixime API?

The market for Cefixime API is expected to remain stable, driven by its established therapeutic role. Emerging trends focus on process optimization, sustainability, and the development of combination therapies.

• Process Innovation: Continued research into more efficient and environmentally friendly synthesis routes is anticipated. This includes the use of biocatalysis or flow chemistry to reduce waste and energy consumption.
• Sustainability: Increasing pressure from regulators and consumers is driving demand for APIs manufactured with sustainable practices. This involves reducing solvent use, improving energy efficiency, and minimizing waste generation.
• Combination Therapies: While Cefixime is primarily used as a monotherapy, there is ongoing research into fixed-dose combinations with other agents to broaden its spectrum of activity or combat resistance. This could indirectly impact API demand for Cefixime or its related compounds.
• Antimicrobial Resistance: The growing threat of antimicrobial resistance may lead to a re-evaluation of first-line antibiotic choices. However, Cefixime remains a valuable option for many common infections where resistance patterns are favorable.
• Quality and Compliance Focus: Regulatory scrutiny on API quality and impurity control is expected to intensify. Manufacturers will need to invest in advanced analytical techniques and robust quality management systems to meet evolving standards.

Key Takeaways

• China and India are the dominant global sources for Cefixime API, with numerous manufacturers possessing significant production capacity.
• Compliance with cGMP and pharmacopoeial standards (USP, EP, JP) is mandatory for market access, particularly in regulated territories.
• While composition of matter patents have expired, ongoing patent activity focuses on novel synthesis processes and crystalline forms.
• Cefixime API pricing is competitive, typically ranging from $25-$50 per kilogram, influenced by production scale, quality certifications, and raw material costs.
• Supply chain resilience depends on secure raw material sourcing, diversified manufacturing, stringent quality control, and navigation of geopolitical risks.
• Future trends include process innovation for sustainability, potential impact from combination therapies, and increasing regulatory demands on API quality.

Frequently Asked Questions

1. What are the primary raw materials for Cefixime API synthesis? Key raw materials typically include 7-aminocephalosporanic acid (7-ACA) or related cephalosporin intermediates, and various side-chain precursors and reagents.

2. How can I verify the GMP compliance of a Cefixime API supplier? Verification can be achieved by reviewing the supplier's regulatory inspection history (e.g., FDA Establishment Inspection Reports), requesting copies of their DMF/ASMF filings, and conducting on-site audits.

3. What is the typical shelf life of Cefixime API? The shelf life of Cefixime API is generally between 2 to 5 years, depending on its specific crystalline form, packaging, and storage conditions. Stability data provided by the manufacturer is crucial.

4. Are there any significant geographical restrictions on Cefixime API sourcing? While sourcing is global, specific markets have stringent import requirements and regulatory approvals. Manufacturers must hold relevant certifications and have DMFs/ASMFs accepted by regulatory bodies in their target countries.

5. What impact does the prevalence of antimicrobial resistance have on the demand for Cefixime API? Antimicrobial resistance can lead to shifts in prescribing patterns. While Cefixime remains a valuable agent for susceptible infections, increasing resistance to third-generation cephalosporins in certain pathogens may, over time, reduce its utility in specific clinical scenarios, potentially impacting long-term demand.

Cited Sources

[1] U.S. Food and Drug Administration. (n.d.). Guidance for Industry: ANDAs—Pre-Approval Inspections. Retrieved from [FDA website] [2] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from [EMA website] [3] World Health Organization. (n.d.). Good manufacturing practices for pharmaceutical products. Retrieved from [WHO website] [4] United States Pharmacopeia. (2023). Cefixime. In USP-NF. Retrieved from [USP website] [5] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Active Substance Master File (ASMF). Retrieved from [EDQM website] [6] National Institutes of Health. (n.d.). DailyMed: Cefixime. Retrieved from [DailyMed website] [7] China National Intellectual Property Administration. (n.d.). Patent Search Database. Retrieved from [CNIPA website] [8] Indian Patent Office. (n.d.). Patent Search. Retrieved from [Indian Patent Office website]